

# Aide-Mémoire

## Minister Seymour meeting with representatives of American Chamber of Commerce Australia (AmCham)

<b>Date due to MO:</b>	3 March 2026	<b>Date of Meeting:</b>	4 March 2026
<b>Security level:</b>	IN CONFIDENCE	<b>Reference:</b>	H2026077778
<b>To:</b>	Hon David Seymour, Associate Minister of Health		
<b>Consulted:</b>	Pharmac: <input checked="" type="checkbox"/>		
<b>Proactive release:</b>	This <b>title</b> is proposed by the Ministry of Health for proactive release: <input type="checkbox"/>		

### Contact for telephone discussion

Name	Position	Telephone
Allison Bennett	Group Manager, Health System Settings, Strategy and Policy	s 9(2)(a)
Alison Cossar	Manager, System Enablers, Strategy and Policy	

PROACTIVELY RELEASED

# Aide-Mémoire

## Minister Seymour meeting with representatives of American Chamber of Commerce Australia (AmCham)

**Date due:** 3 March 2026

**To:** Hon David Seymour, Associate Minister of Health

**Security level:** IN CONFIDENCE

**Reference:** H2026077778

### About the Meeting

**Purpose of Meeting:**

The American Chamber of Commerce (AmCham) Australia have requested this meeting to:

- discuss your priorities for the health system
- discuss how industry can best engage to support the sustainability of New Zealand's health system

**Details of Meeting:**

**Date:** 4 March 2026  
**Time:** 12:00pm – 12.30pm  
**Venue:** Legislative Council Chamber

**Attendees**

The AmCham health delegation of senior executives from major Australian, New Zealand and global healthcare companies. Biographies are included in Appendix 1.

**Organisation**

AmCham Australia provides a network for US and Australian companies and supports with promoting trade, commerce, and investment to and from Australia. AmCham regularly conducts international trade delegations, study tours, and summits, strengthening economic ties and building personal relationships between the US and Australia.

**Ministry representatives**

Officials are available to attend at your request

**Other information**

Hon Simeon Brown, Hon Casey Costello and Hon Matt Doocoy are also meeting with AmCham separately on 4 March. The following have been included to support you at the meeting:

- Background on your current priorities and AmCham
- Appendix 1: Biographies

## Background and context

1. AmCham Australia is the largest and most active international chamber of commerce in Australia. They represent significant Australian and American companies and start-ups operating in the Indo-Pacific region. Many of AmCham Australia's members also oversee the company's operations in New Zealand.
2. AmCham Australia and AmCham New Zealand recently held their annual conference for 2026 on 2-3 March in Wellington. The conference discussed the topics of Health, Defence & Security, Technology & Artificial Intelligence, and US Politics and Economic Outlook for the year ahead. Hon Nicola Willis was a keynote speaker.
3. AmCham Australia have not provided an agenda for this meeting aside from indicating an interest in discussing progress on Pharmac, an update on the priorities of your health portfolio and how their companies can best engage to support New Zealand's health system.
4. AmCham Australia may also be interested in discussing changes to therapeutic regulation such as the verification pathway and the Medical Products Bill, Medsafe's processes, and the evolving approach to Health Technology Assessments (HTA) and medical devices. Each are laid out in detail below.
5. The health delegation will meet with Ministers Brown, Doocey and Costello to discuss their health portfolios. AmCham previously met with these Ministers during last year's annual conference in June 2025.

## Areas of Discussion

### Associate health portfolio priorities

6. Understanding your health priorities provides opportunities for industry to tailor their engagement strategies for New Zealand.
7. Your portfolio priorities for 2026 focus on improving access to medicines and Pharmac's processes with current work centred on three main areas:
  - a. Improving regulatory efficiency:
    - Developing the **new verification approval pathway** to increase Medsafe's regulatory efficiencies.
    - Progressing **industrial hemp regulatory reform**. Announcements on regulatory changes will be made in April 2026.
  - b. s 9(2)(f)(iv)
  - c. Holding Crown Entities to account through clear governance, performance expectations, and regular monitoring, particularly in relation to **Pharmac** and for **medical devices**.

## Pharmac

8. Pharmaceutical companies invest heavily in R&D for new medicines and will likely be interested in understanding how New Zealand values innovation in medicines and pathways for market access.
9. The Pharmac model uses competitive tendering and cost-effectiveness assessments to lower medicine prices. Some areas of challenge for industry in the past have included:
  - Limited transparency of Pharmac decision-making criteria
  - The Pharmac HTA process valuing cost-containment over innovation
  - Lengthy procurement timelines
  - Limited engagement with consumers and industry
10. AmCham may be interested in understanding how these issues are being addressed.
11. The Government has continued to work with Pharmac and monitor progress against the 2022 Pharmac Review, with a particular focus on decision-making, governance, and transparency. As of October 2025, 8 expectations have been fully completed including:
  - Proactively publishing material of public interest, and establishing a monthly consumer update forum. This forum gives consumers the opportunity to hear from Pharmac's Senior Leadership Team and provide feedback following independent engagement workshops.
  - Accelerated efforts to collaborate with health sector partners, including the establishment of the Health Sector Implementation Group and the Sector Equity Working Group.
  - Regularly reporting to track organisational culture and stakeholder sentiment, supported by quarterly and annual performance measures.
  - Continued review of statutory objectives and functions, with proactive engagement on legislative updates and medical technology procurement.
  - Strengthened consumer participation in decision-making, regular consultation with advisory groups, and improved transparency of clinical advice records.
12. Progress on HTA processes is discussed in the medical devices section below.

### **Verification Pathway (Rule of Two)**

13. AmCham's membership will likely have strong commercial interest in faster and more predictable regulatory routes for introducing medicines into the New Zealand market.
14. The Verification Pathway or "Rule of Two" has been introduced through the Medicines Amendment Act 2025, which will enable medicines to be approved in 30 working days if the product has approval from two recognised overseas jurisdictions. This streamlines the pathway for new medicines approvals in New Zealand.
15. Due to the technical nature of the verification pathway, the Medicines Act 1981 provides for its operational policies to be set through secondary legislation (Rules) made by the Minister of Health, delegated to you as Associate Minister of Health. Public consultation undertaken by the Ministry of Health (the Ministry) on the Rules commenced in February 2026.

16. Industry has been consulted by Medsafe throughout the development of the Verification Pathway and will be able to engage through the formal consultation process on the Rules and Fees.
17. We expect the Verification Pathway will be able to start operating in June 2026.

## Medical Products Bill

18. AmCham and wider industry have shown ongoing interest regarding the development of the new Medical Products Bill (the Bill).
19. Whilst Minister Costello is responsible for progressing the Bill, the below information provides context to support discussion with the AmCham delegation, where necessary.
20. Cabinet agreed in September 2024 to proceed with the Bill which will replace the Medicines Act 1981 with modern, flexible and fit-for-purpose regulation of medicines and medical devices.
21. The Bill will regulate medicines and medical devices in a risk-proportionate and internationally aligned way. It will support innovation, competition, economic growth, and exports, while maintaining New Zealand's reputation for high-quality products.
22. Industry has been closely consulted on the Bill. Industry is keen for the Bill to promote and enable international harmonisation of standards and product approval processes and also greater recognition of decisions made by trusted regulators (such as Australia's Therapeutic Goods Administration and the US Food and Drug Administration).
23. The Bill will introduce a modern, risk based regulatory framework for medical devices, reducing duplication of due diligence through reliance on trusted overseas approvals, and improving visibility of the device supply chain. It will also allow domestic manufacturers to obtain local approvals that facilitate access to overseas markets.
24. The Bill supports innovation in the MedTech sector by introducing flexible approval pathways for novel and patient matched technologies. This includes approval of both products and their manufacturing processes, which is an essential step for advancing personalised and genomic medicines.

### *Next steps for medical product regulation*

25. The Ministry is working to prepare the Bill for introduction to Parliament in late 2026.

## Medical technology and devices

26. Industry interests in New Zealand's medical technology environment are likely to include:
  - Regulatory alignment – New Zealand enhancing regulatory harmonisation with international standards.
  - Market access – transparent and predictable processes from Pharmac to support companies to evaluate market viability of their products.
  - Data interoperability and digital health infrastructure – including in the context of clinical trials.

27. As outlined above, the Medical Products Bill will introduce a new regulatory framework for medical devices, aligning New Zealand with international best-practice. The proposed approvals regulations will be risk-proportionate, meaning only around one percent of new devices – highest-risk products without trusted overseas approval – would require local review. The medical device sector has responded positively to announcements about the Medical Products Bill.

*Better procurement of medical devices*

28. In September 2025, the Government announced Pharmac and Health New Zealand (Health NZ) would share the procurement of 55 medical device categories, with Pharmac delegated responsibility for 27 categories and Health NZ leading on 28.
29. This change allows for Pharmac and Health NZ to be able to procure medical devices that are most focused on their particular capabilities and expertise. A clear split between the agencies will provide the transparency and certainty that suppliers have been asking for.
30. This approach includes an arrangement for Health Technology Assessments (HTAs) to inform decisions about which medical devices to prioritise for the health system, which is intended to help drive innovation.
31. Health NZ, with support from the Ministry, has developed the Health Technology Evaluation Pathway (HTEP). This pathway will guide decision-making and implementation for health technologies to ensure that spending on health technologies (such as genomics and artificial intelligence) is focused on value for money, patient outcomes, and alignment with health targets.
32. Pharmac has been involved in the development of HTEP to ensure coordinated, system-wide value assessment of health technologies.


*Next steps for medical devices procurement*

33. Industry engagement will continue to be important, and the Medical Technology Association of New Zealand (which is a member of AmCham NZ) has previously signalled strong interest in working collaboratively with agencies. To support this, agencies are establishing a Supplier Reference Group made up of key industry stakeholders to provide insights into the supplier experience as the new medical device procurement approach is implemented.
34. The Ministry is due to provide you with an update on the progress made by Pharmac and Health NZ on the new approach in March 2026.

s 9(2)(g)(i)

s 9(2)(g)(i)

PROACTIVELY RELEASED



Alison Cossar  
Manager, System Enablers  
**Strategy and Policy**

## Appendix 1: Biographies (see attachment)

PROACTIVELY RELEASED



AmCham

# HEALTH DELEGATION

WELLINGTON, NZ

MARCH 4, 2026



**Steve Dodd**

*Genomic Solutions and  
BioSciences Manager  
NZ,  
Thermo Fisher Scientific*

Steven is the New Zealand Genomic Solutions and BioSciences Manager for Thermo Fisher Scientific. Originally from the small town of Opunake, Taranaki, he attended the University of Otago from 1994-2002 where he completed a BSc (microbiology), MSc (Microbiology) and PhD (molecular biology/genetics) in conjunction with AgResearch.

He has 22 years' experience in the Life Science and Diagnostic industry with Thermo Fisher Scientific and its legacy companies, Life Technologies and Invitrogen. This experience includes direct field sales and high-level negotiation across Cambridge (UK), New Zealand and Australia, as well as people management and coaching.

He returned to New Zealand in April 2014 to take up a commercial role for the Life Sciences Solutions Group (formerly Life Technologies) of Thermo Fisher Scientific which involves management of the New Zealand Life Sciences team. He is a member of the ANZ leadership team and actively contributes to the business development strategy and employee wellbeing.



ThermoFisher  
SCIENTIFIC

Thermo Fisher Scientific is a diversified science innovation, biotechnology, and biomanufacturing company with a mission to help (enable our customers) make the world healthier, cleaner, and safer.

Through its products and service, Thermo Fisher plays a leading role in enabling the development and scaling of major scientific advances in health (diagnostics, medicine & vaccine manufacturing, clinical trials, genomics, advanced therapies, etc.), food safety, environment, clean energy, mining, biosecurity, border security, and law enforcement.

Thermo Fisher is a US\$40B+ (revenue) business with a market capitalisation of US\$240B, employing over 130K colleagues around the world (1,700+ across AU & NZ), and invests over US\$1.3B in R&D every year.



**Aliza Glanville**  
*Country Commercial  
Director New Zealand,  
Bristol Myers Squibb*


Aliza Glanville, a senior executive and board director with extensive leadership experience across global biopharmaceutical and healthcare organisations in New Zealand and Australia. Aliza is currently Country Commercial Director for Bristol Myers Squibb New Zealand and has previously served as a Board Director and Commercial Lead within multinational organisations. She brings deep expertise in commercialisation, market access, governance, and go-to-market strategy, and has successfully led high-performing teams and governed multinational businesses exceeding \$300 million in revenue. Known for her strategic insight, collaborative leadership style, and strong stakeholder engagement, Aliza is passionate about driving sustainable growth and improving outcomes for patients and healthcare systems. She holds a Bachelor of Science in Neuroscience and Pharmacology, postgraduate qualifications in Marketing and Business Administration, and is progressing toward Chartered Director status with a Certificate in Company Direction.



Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines for patients with serious diseases. Guided by a strong focus on science and patient outcomes, the company concentrates on areas of high unmet medical need and applies differentiated research platforms and therapeutic modalities to advance medical innovation and improve health outcomes worldwide.

Bristol Myers Squibb works collaboratively with governments, health systems, clinicians, researchers and patient communities to support timely access to innovative therapies and to contribute to sustainable, evidence-based healthcare systems. The company's approach emphasises the responsible generation and use of clinical and real-world evidence, the translation of scientific advances into meaningful patient benefit, and the long-term value of innovation in addressing complex and serious diseases.

Through its global footprint and partnerships, Bristol Myers Squibb seeks to support public health priorities, strengthen health system resilience and contribute constructively to policy discussions focused on improving patient outcomes, equity of access and the sustainability of healthcare systems. The company is committed to operating with integrity, transparency and accountability in its engagement with governments and public institutions.



**Mike Hearn**  
*Executive Director,  
AmCham New Zealand*

Mike Hearn was educated in the UK and has been in New Zealand since 1981. He has a background in international banking and trade finance in the UK, USA, and New Zealand. Mike has been the Executive Director of the American Chamber of Commerce in New Zealand Inc. since 1998. Mike is Chairman and Trustee of New Zealand Robotics Charitable Trust since 2008 – teaching kids robotics using the Vex program. Mike is an Executive Committee member of the Canada New Zealand Business Association Inc since 1988, a former Board member of US-NZ Council, Washington, DC, USA 2000- 2014; and former Board member of NZ-US Council, Auckland, 2004-2014.



AmCham New Zealand has been promoting trade, investment, tourism and education links between the United States of America and New Zealand for almost 60 years. Their membership is diverse and is made up of many of the US Fortune 500 companies and leading NZ corporates, and SME's representing turnover well in excess of \$50 billion and over 100,000 employees.

They work closely with many organisations, governmental and business, in both countries as well as with our counterparts in the Asia-Pacific region and this network provides their members with access privileges other organisations are unable to provide.



**Kate King**  
*Government Affairs  
Director,  
Medtronic*

Kate joined Medtronic in early 2019 in a senior Government Affairs and Policy role. Prior to commencing with Medtronic, Kate worked in the financial services sector leading a project with large corporates and the not-for-profit sector focussed on building greater resilience to natural disaster events.

Previously, Kate spent over a decade working in diverse public policy roles in Australia, including in senior roles in Ministerial Offices, and also in the United Kingdom's Cabinet Office. She also has experience in the not-for-profit sector in the UK.

Kate is on the MTAA's Public Affairs Committee, and was elected to the Board of the Medical Technology Association of New Zealand in June 2024. Kate is also the Chair of the AMCHAM Health Committee.

## Medtronic

Medtronic is a global leader in medical technology, services and solutions with our mission to alleviate pain, restore health, and extend life. At Medtronic we aim to transform the lives of our patients, by utilising the latest ground-breaking technology while leveraging our deep understanding of the human body.

Medtronic provides a wide range of products, therapies, and services with the aim of providing a complete continuum of care to diagnose, prevent, treat, and monitor chronic and acute conditions.

Our therapies and solutions span four portfolios to treat more than 70 conditions in the human body across Cardiovascular, Medical Surgical and Neuroscience. Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people's lives.



**Clinton Lubcke**  
*Senior Manager -  
Government Relations,  
Stryker*

Clinton has over 20 years of healthcare industry experience across government affairs, market access, public policy and sales & marketing. He joined Stryker in August 2021, after having previously served as Head of Market Access & Government Affairs ANZ at Baxter Healthcare.

Clinton has worked across both MedTech and Pharma sectors, fostering strong relationships between business and policymakers and is an active contributor to the ongoing advocacy efforts of the Medical Technology Association of Australia (MTAA), Medical Technology Association of NZ (MTANZ) and the American Chamber of Commerce in Australia. Clinton played an important role in ensuring ongoing access to Australian made IV fluids during the Covid pandemic and has gone on to positively influence policy agendas in a diverse array of fields including advanced manufacturing, home based care and surgical robotics.

Clinton holds tertiary qualifications including a BSc (Hons) - University of Western Australia, Grad Dip Biotechnology - Melbourne University and Grad Cert Pharmacoeconomics - Monash University.

**stryker**

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at [www.stryker.com](http://www.stryker.com).



**James McAdam**  
*Director, Government  
Affairs, Policy and  
Advocacy,  
Bristol Myers Squibb*

James commenced at Bristol-Myers Squibb in 2017. Prior to his arrival at BMS, James was Senior Adviser in the office of the Minister for Health and Sport. This senior role provided an opportunity to influence policy development and its implementation within healthcare in Australia.

James has developed a strong background in policy, advocacy and government relations gathered over many years working in government, healthcare and the information technology and communications industries. He worked in various roles in campaign politics and for individual Members of Parliament and ministers, before moving into government relations and senior management roles within industry bodies.

In healthcare, James has held positions as Director of Relationships & Advocacy at the Royal Australasian College of Surgeons and as CEO of the Royal Australian & New Zealand College of Obstetricians and Gynaecologists. He served one term as a Director of Eastern Health, Melbourne's largest area health service.

In his role at BMS James is recognised as a leader in policy development and advocacy, articulating complex policy concepts and driving change in diverse areas such as clinical trial reform, PBS/HTA reform and cancer care navigation.


James holds a Bachelor of Arts and post graduate qualifications in humanities and education from La Trobe University. He is a Graduate of the Australian Institute of Company Directors and a Fellow of the Centre for Corporate Public Affairs.



Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines for patients with serious diseases. Guided by a strong focus on science and patient outcomes, the company concentrates on areas of high unmet medical need and applies differentiated research platforms and therapeutic modalities to advance medical innovation and improve health outcomes worldwide.

Bristol Myers Squibb works collaboratively with governments, health systems, clinicians, researchers and patient communities to support timely access to innovative therapies and to contribute to sustainable, evidence-based healthcare systems. The company's approach emphasises the responsible generation and use of clinical and real-world evidence, the translation of scientific advances into meaningful patient benefit, and the long-term value of innovation in addressing complex and serious diseases.

Through its global footprint and partnerships, Bristol Myers Squibb seeks to support public health priorities, strengthen health system resilience and contribute constructively to policy discussions focused on improving patient outcomes, equity of access and the sustainability of healthcare systems. The company is committed to operating with integrity, transparency and accountability in its engagement with governments and public institutions.



**Nicholas McGee**  
*Head of Government  
Relations & Policy,  
MSD*

Nick is the Head of Government Affairs and Policy for Merck Sharp & Dohme (MSD) Australia & New Zealand. In this role Nick is responsible for overseeing all policy and government relations activities for the company across all of ANZ. Prior to joining MSD, Nick worked in various roles within the pharmaceutical industry and across other industries. Nick is based in Sydney.



At MSD, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities.



**Aditi McManus**  
*Head of Government  
Affairs ANZ,  
Varian*

Aditi is the Head of Government Affairs, Australia & New Zealand, at Varian, a Siemens Healthineers company. Varian is a global leader in providing technology for cancer care, specialising in radiation therapy. Varian is headquartered in Palo Alto, US.

Aditi has extensive experience in government relations, policy development, stakeholder management and healthcare.

Aditi has held policy leadership roles at the Australian Human Rights Commission, Disability Royal Commission, NSW Health and NSW Premier's Department.

Before coming to Varian, Aditi was the Principal Policy Officer and acting Director of Community Care and Priority Populations at NSW Health in Australia, where she led policy development, program design, and strategic partnerships across various priority population groups, including primary care, women's health, LGBTIQ+ health, refugee and multicultural health.

Aditi is passionate about influencing policy as a pivotal lever to improve health and social equity. Aditi won the inaugural Scope Global Young Achievers Award at Parliament House, Australia, in recognition of her volunteer work in Sri Lanka and as a future change maker.

Aditi holds a Master of Human Rights, Bachelor of Social Work (Honours) and Bachelor of Arts from the University of Sydney.

Aditi is excited to use her expertise and experience to contribute to the development of a vibrant, sustainable healthcare system that promotes innovation and delivers best practice for Australians of all ages and backgrounds.



Varian, a Siemens Healthineers company, develops and delivers advanced technologies that diagnose, plan and treat cancer. We provide radiation therapy systems, imaging solutions, treatment planning software and digital tools that enable clinicians to deliver precise, personalised cancer care. Our technologies support hospitals and cancer centres across the full care pathway — from detection and treatment planning through to therapy delivery and follow-up. By integrating imaging, software and treatment systems, we help clinicians improve accuracy, efficiency and patient outcomes. Together with our partners, we are building a connected oncology ecosystem designed to make high-quality cancer care more accessible worldwide.



**Angela Pantano**  
*Chapter Lead,  
Access and Innovation,  
Roche*

Starting with over 15 years of clinical nursing experience across New Zealand and England, Angela brings a deeply patient-centric approach in her commercial healthcare leadership roles. Her career is defined by a passion for "working with people, for people," blending a high-level understanding of healthcare delivery with a proven track record in global commercial strategy.

She specialises in navigating complex healthcare policy and access landscapes and successfully commercialising innovative products.

Her expertise includes:

- **Global Commercialization:** Navigating regulatory and reimbursement pathways to launch products across 15 international markets, including Europe, Asia, and Africa.
- **Strategic Leadership:** Leading high-performing, multidisciplinary teams—from managing 65 nurses in Middlemore Hospital's NICU to directing affiliate teams in challenging funding environments.
- **Commercial Acumen:** Expertise in payer negotiations, strategy development, and startup growth within the MedTech and biotech sectors.

By combining innovative thinking with a collaborative leadership style, she has consistently achieved success in some of the world's most demanding healthcare markets. Angela remains committed to driving excellence in patient outcomes through commercial innovation and authentic partnership.



Roche Diagnostics is part of the Roche Group and is a leading global supplier of diagnostics solutions covering a broad spectrum of medical conditions including cardiovascular disease, infectious disease, oncology and women's health. Roche is a leader in in-vitro diagnostics (IVDs) and tissue-based cancer diagnostics. In 2021, over 27 billion tests were performed globally using one of our solutions. Roche's Diagnostics division in NZ also employs over 50 people and has a broad range of in-vitro diagnostics, digital healthcare tools, disease management and clinical decisions support products. Roche Diagnostics serve customers spanning the entire healthcare spectrum - from research institutions, hospitals and commercial laboratories to physicians and patients.



**Brad Porter**  
*Chief Executive Officer,  
Orion Health*

Brad Porter was appointed Chief Executive Officer of Orion Health in August 2022 and now also serves in a dual capacity as Chief Commercial Officer for HEALWELL AI. His expanded role reflects the central position Orion Health holds as HEALWELL's largest and most global business, as well as the opportunity to shape the group's commercial direction on a global scale.

In this expanded capacity, Brad leads the development of HEALWELL's commercial strategy and is responsible for scaling HEALWELL AI's capabilities across international markets, building on the momentum already created through Orion Health's strong customer base, trusted technology platforms, and global partnerships.

Brad brings deep expertise in commercial strategy, global sales, and market expansion. Prior to joining Orion Health, he was General Manager Commercial (International Sales) at Fisher & Paykel Healthcare, where he supported a global sales force of 1,300 across 53 countries. During his tenure, company revenue grew from NZ\$800 million to nearly NZ\$2 billion.

His career began at KPMG, followed by investment and advisory roles at Collier Capital and Kinetic Partners in London. Upon returning to New Zealand, he joined Fisher & Paykel Healthcare's sales team, rising through the ranks to take on global leadership responsibilities.

Brad is passionate about aligning local innovation with international opportunity and delivering scalable digital health solutions that improve population health outcomes and health system sustainability.



Orion Health, a HEALWELL AI company, is a global healthcare technology company focused on reimagining healthcare for all. We are leading the change in digital health by working with health and care organisations to improve the wellbeing of every individual through AI-driven insights, smarter decision-making, and more intelligent coordination across the entire health journey. Orion Health's Unified Healthcare Platform, comprised of the Virtuoso Digital Front Door and the Amadeus Digital Care Record, is underpinned by extensive health and social data sets, machine learning, and over 30 years of innovation focused purely on improving global wellbeing.



**Amie O'Mahony**  
*General Manager,  
Government Relations,  
AmCham Australia*

Amie O'Mahony joined AmCham in 2013 after a respected career in law. She is based in Sydney.

As General Manager Government Relations, she is responsible for managing all aspects of government affairs, industry and business engagement for the Chamber including acting as Secretariat for AmCham's numerous policy committees and leading advocacy efforts on trade and investment issues impacting members.

Amie began her career as a lawyer specialising in corporate, litigation and insolvency over 14 years ago. An experienced professional, both in Australia and the UK, she has an extensive background in government relations, strategic thinking, negotiation, business development, project management, and stakeholder relations.

Amie is a member of the National Trade Facilitation Committee.

She has a Bachelor of Law from Queensland University of Technology and a Master of Business Administration from Macquarie Graduate School of Management.



The American Chamber of Commerce in Australia (AmCham) is the country's largest international chamber of commerce and premier international business organisation. Founded in 1961, AmCham is known for providing high-level access to opportunity for leading Australian businesses, including over 600 corporate members. AmCham regularly conducts international trade delegations, study tours, and summits, strengthening economic ties and building personal relationships between the United States and Australia.



**Andrew Thirlwell**  
*Director Global Policy  
and Public Affairs ANZ,  
Pfizer*

Accomplished executive with over 20 years' experience in the life sciences sector in APAC and the UK recognised for leading high performing teams. Adept at navigating complex regulatory environments, market access, crisis management, building coalitions and gaining trust. Passionate about developing colleagues to their full potential with a growth mindset approach building on their strengths.

Inspired by innovation and making sure it reaches those that need it most.



Pfizer is the world's largest leading research-based healthcare company and has a history of more than 115 years in Australia. Pfizer researches, manufactures and markets many of the world's leading medical and healthcare treatments for both humans and animals.



**Matthew Tyson**  
*Senior Manager, Market  
Access and Partnerships,  
Johnson & Johnson*

Matthew Tyson is the Senior Manager for Market Access and Partnerships at Johnson & Johnson, leading strategic initiatives to accelerate access to healthcare innovation for New Zealanders. With extensive experience navigating complex public and private health ecosystems, Matthew works at the intersection of government, industry, and clinical stakeholders to shape sustainable pathways for new technologies and solutions.

## Johnson & Johnson

Johnson & Johnson, is a global pharmaceutical company and a subsidiary of Johnson & Johnson Corporation. A member of the top 10 pharmaceutical companies globally, J&J has 40,000 employees working across five continents and invests approximately \$4.5 billion in research and development annually. The J&J team in NZ consists of 4.5 full time employees, and reports into the Australian-New Zealand head office based in Sydney.

Guided by our CREDO, J&J provides prescription medicines for a range of conditions in the areas of haematology, immunology, oncology, mental health, virology, diabetes, neurology, and pain management.



**Chris Wynne**  
*Chief Scientific Officer,  
New Zealand Clinical  
Research*

Dr Chris Wynne is a physician with expertise in developing new medicines. He has had a clinical career as an oncologist working in Australia, UK, Singapore and New Zealand and is now the Chief Scientific Officer at New Zealand Clinical Research.

His role at NZCR involves engaging with pharmaceutical and biotech companies to transition potential new drugs from the lab and test them in humans for safety and effectiveness. He is responsible for the assessment of the safety of new trial drugs and the integrity of data from clinical trials.

Chris supports the growth of the commercial clinical trial industry in New Zealand by:

- Providing high level scientific advice to biotech and pharma companies
- Training of specialised clinical research physicians and other clinical trial staff
- Supporting efficient regulatory approval for clinical trials

His clinical interests include development of new non-addictive pain drugs, novel drugs for diabetes and weight loss, and gene modifying drugs.



New Zealand Clinical Research group is New Zealand's leading clinical trials company with over 25 years experience in developing new medicines.

With a focus on novel drug research and a commitment to participant safety, NZCR has established itself as a trusted partner for biotech and pharma companies in the development of new medicines and medical treatments. The ability to perform complex clinical research in healthy participants and patients, within New Zealand's robust regulatory environment, has attracted many big Pharma companies to work with NZCR.

As a physician-led organisation employing 900 people, NZCR has a track record of completing over 800 trials involving over 17,000 participants. These studies range from first-in-human clinical trials to phase 3 patient studies, covering research across the entire lifecycle of drug development.

NZCR has early phase dosing units located in Auckland and Christchurch, plus two recruitment and outpatient sites located in Hamilton and Wellington. Later phase trials are conducted by Optimal Clinical Trials, a company within the NZCR group. The recent acquisition of CMax, an Adelaide based clinical trial company, has extended NZCR's capability to recruit healthy participants and patients across a wide range of disease types within another regulatory jurisdiction.

Current exciting areas of research involving NZCR physicians include non-addictive pain drugs, diabetes, obesity, liver disease and gene modifying therapy for common and rare diseases. A full list of current trials, leadership information and further NZCR background is available at [www.nzcr.co.nz](http://www.nzcr.co.nz)